Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
Holding IPSC?
Track your performance easily
IPSC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $5.51
Previous Close$1.1
Volume1.02M
Average Volume (3M)541.52K
Market Cap
$89.28M
Enterprise Value-$57.99M
Total Cash (Recent Filing)$198.11M
Total Debt (Recent Filing)$50.84M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Mar 13, 2025EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding85,029,042
10 Day Avg. Volume844,958
30 Day Avg. Volume541,524
Standard Deviation0.29
R-Squared0.08
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)33.25
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-29.32
Enterprise Value/Gross Profit-25.95
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$8.50Price Target Upside672.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Century Therapeutics News
PremiumCompany Announcements
Century Therapeutics Faces Termination of BMS Agreement
PremiumCompany Announcements
Century Therapeutics Reports Q3 Results & Strategic Updates
Bulls Say, Bears Say
Bulls Say
Clinical Program OutlookThe outlook for Century's lead clinical program, CNTY-101, remains positive despite the termination of the BMS collaboration.
Response Rate In TrialsCentury Therapeutics announced updated Phase 1 data for CNTY-101 in CD19+ B cell lymphomas with an 83% overall response rate and 33% complete responses.
Therapeutic PotentialThe therapeutic potential and dosing flexibility of Century Therapeutics' Allo-Evasion technology promises superior clinical outcomes with CNTY-101 in autoimmune diseases.
Bears Say
Market CompetitionThe CD19 cell therapy space is crowded, resulting in limited opportunity in B cell lymphomas.
Partnership TerminationBMS' decision to discontinue their collaboration agreement with Century is disappointing and attributed to 'an internal corporate portfolio prioritization process.'
Sales Forecast ReductionCentury Therapeutics has reduced its peak worldwide sales model for CNTY-101 from $3.4B to $2.0B due to market constraints.
---
Ownership Overview
3.40% Insiders
6.29% Mutual Funds
29.27% Other Institutional Investors
55.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.98 and its highest was $5.51 in the past 12 months.
What is Century Therapeutics’s market cap?
Currently, no data Available
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.451 by $0.081.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -$0.41.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 85,029,045 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.451. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Century Therapeutics?
Among the largest hedge funds holding Century Therapeutics’s share is Baker Bros Advisors LP. It holds Century Therapeutics’s shares valued at 1M.
---
Century Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (672.73% Upside)
$8.50 (672.73% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 66%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $22.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.58%
12-Months-Change
Fundamentals
Return on Equity
-62.61%
Trailing 12-Months
Asset Growth
-2.25%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
---
IPSC Stock 12 Month Forecast
Average Price Target
$8.50
▲(672.73% Upside)
Technical Analysis
Adaptive Biotechnologies
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering IPSC
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-39.87%
reiterated a buy rating 2 months ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -39.87% per trade.
---